DPBIO

Dropx Biotech Limited, incubated at the Hong Kong University of Science and Technology and founded in 2018, is a leading Chinese company in the field of droplet microfluidics, committed to providing world-class life science solutions. The company has research and development centers in Shenzhen, Jiaxing, and Hong Kong, with a nearly 100-person R&D team focused on applying droplet microfluidic technology to biomedicine and precision medicine. It aims to become a comprehensive solution provider integrating the R&D and production of microfluidic chips, instruments, and reagents. Several scientific instruments based on droplet microfluidic technology have been successfully commercialized, including the Comet High Throughput Sorting System, Galaxy Single Cell Analysis System, and Nebula dPCR System. These products can be applied in areas such as antibody screening, enzyme evolution, synthetic biology, high-throughput drug screening, cancer research, early cancer detection, targeted therapy, non-invasive prenatal diagnosis, virus quantification, and biopharmaceutical quality inspection. To date, the company has served over 100 leading biopharmaceutical companies, research service providers, and IVD enterprises in China, earning widespread recognition within the industry.